For NEW Patient Copay Assistance information, please click on this link
Teva’s Shared Solutions® is committed to helping your patients find affordable access to AJOVY
Patient Services PortalThe support team at CoverMyMeds® can help resolve or automatically initiate PA requests
CoverMyMeds®Get your patients started on AJOVY. Begin here
This information should not be construed to imply any difference in safety, efficacy, or other clinical outcome. View the safety profile of AJOVY.
*Washout period defined as time until plasma concentrations of AJOVY are below a clinically relevant concentration and thus considered eliminated.
The mechanism of action for AJOVY
involves exclusive binding of CGRP
AJOVY does not exhibit off-site binding
of related calcitonin family members
In clinical trials:
The relationship between pharmacokinetics and efficacy has not been established.
AJOVY was evaluated in a phase 1 study to assess pharmacokinetic parameters for both monthly and quarterly dosing in healthy volunteers.5
Serum concentrations of AJOVY were sustained throughout both the monthly and quarterly dosing period4
‖Washout period defined as time until plasma concentrations of AJOVY are below a clinically relevant concentration and thus considered eliminated.
Introducing AJOVY (fremanezumab-vfrm) injection, indicated for the preventive treatment of migraine in adults.
IMPORTANT SAFETY INFORMATION
Contraindications: AJOVY is contraindicated in patients with serious hypersensitivity to fremanezumab-vfrm or to any of the excipients. Reactions have included anaphylaxis and angioedema.
AJOVY (fremanezumab-vfrm) injection is a monoclonal antibody targeting the calcitonin gene-related peptide, or CGRP, ligand.
Patients experiencing migraine have increased levels of CGRP, a neuropeptide present in both the central and peripheral nervous system.
When CGRP binds to its receptor, a cascade of events result, which contribute to neurogenic inflammation that is associated with migraine pain.
This involves mast cell degranulation, vasodilation, and protein extravasation.
AJOVY selectively binds the CGRP ligand, which is believed to block this cascade of events, thereby preventing the activation of the trigeminal system.
CGRP plays an important role in the pathophysiology of migraine.
INDICATION
AJOVY is indicated for the preventive treatment of migraine in adults.
IMPORTANT SAFETY INFORMATION
Contraindications: AJOVY is contraindicated in patients with serious hypersensitivity to fremanezumab-vfrm or to any of the excipients. Reactions have included anaphylaxis and angioedema.
Hypersensitivity Reactions: Hypersensitivity reactions, including rash, pruritus, drug hypersensitivity, and urticaria were reported with AJOVY in clinical trials. Most reactions were mild to moderate, but some led to discontinuation or required corticosteroid treatment. Most reactions were reported from within hours to one month after administration. Cases of anaphylaxis and angioedema have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing AJOVY and institute appropriate therapy.
Adverse Reactions: The most common adverse reactions in clinical trials (≥5% and greater than placebo) were injection-site reactions.
Please see the full Prescribing Information at AJOVYhcp.com.
Teva’s Shared Solutions® is committed to helping your patients find affordable access to AJOVY
Patient Services PortalThe support team at CoverMyMeds® can help resolve or automatically initiate PA requests
CoverMyMeds®
